PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

I think your rationale has a lot of merit about the side effects of other insulin sensitizers. A brief outline of others is as follows:
Chemically, the members of this class are derivatives of the parent compound thiazolidinedione, and include:

Pioglitazone (Actos), France and Germany have suspended its sale after a study suggested the drug could raise the risk of bladder cancer.[4]
Rosiglitazone (Avandia), which was put under selling restrictions in the US and withdrawn from the market in Europe due to some studies suggesting an increased risk of cardiovascular events. Upon re-evaluation of new data in 2013, the FDA lifted the restrictions.
Lobeglitazone (Duvie), approved for use in Korea
Troglitazone (Rezulin), which was withdrawn from the market due to an increased incidence of drug-induced hepatitis.

As for other classes, Metformin is a poor choice in renal insufficiency, a common condition found with diabetes. Other oral type 2 meds have side effects of weight gain and lose effectiveness with time and increased use.
Sucanon, in published studies, ("substantial clinical investigations" in the FDAs words), shows weight loss, decrease in visceral body fat and improved lipid profiles, and no reported adverse side effects.

Excellent insight, and in no way a ridiculous comment. It really is a shame to ridicule what we don't understand.